Financial Data and Key Metrics Changes - No specific financial data or key metrics changes mentioned in the provided content [1][2][3][4] Business Line Data and Key Metrics Changes - No specific business line data or key metrics changes mentioned in the provided content [1][2][3][4] Market Data and Key Metrics Changes - No specific market data or key metrics changes mentioned in the provided content [1][2][3][4] Company Strategy and Development Direction and Industry Competition - Quipt Home Medical is a diversified healthcare services company delivering a comprehensive range of home medical equipment and services to patients across the United States [4] - The company is committed to clinical excellence powered by a patient-centric model and advanced technology-enabled solutions [4] - Quipt has expanded to over 135 locations across 26 states with over 314,000 patients [4] Management's Comments on Operating Environment and Future Prospects - No specific comments on the operating environment or future prospects mentioned in the provided content [1][2][3][4] Other Important Information - The remarks during the call include forward-looking statements that are subject to important risks and uncertainties [1] - The company's actual performance could differ materially from these statements [1] Summary of Q&A Session - No Q&A session content provided in the documents [1][2][3][4]

Quipt Home Medical Corp. (QIPT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.01. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -800%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced a loss of $0.04, delivering a surprise of -500%.Over the last four quarters, the company has surpassed ...

Posts Strong Adjusted EBITDA Margin‎1 ‎for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2024 and a ...

Core Viewpoint - Quipt Home Medical Corp. is set to announce its fiscal fourth quarter and full year 2024 financial results on December 16, 2024, with a conference call scheduled for December 17, 2024, to discuss these results with the investment community [1]. Group 1: Company Overview - Quipt Home Medical Corp. is a U.S.-based provider of home medical equipment, focusing on end-to-end respiratory care [1]. - The company offers in-home monitoring and disease management services, particularly for patients with chronic conditions such as heart or pulmonary diseases, sleep disorders, and reduced mobility [3]. - The primary business objective is to create shareholder value by expanding service offerings to patients in need of in-home monitoring and chronic disease management [3]. Group 2: Growth Strategy - The company's organic growth strategy aims to increase annual revenue per patient by providing multiple services to the same patient, thereby consolidating services and enhancing patient convenience [3].

CINCINNATI, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ: QIPT; TSX: QIPT), a U.S.-based home medical equipment provider, focused on end-to-end respiratory care, today announced its third quarter fiscal 2024 financial results and operational highlights. These results pertain to the three and nine months ended June 30, 2024, and are reported in United States dollars ("$", "dollars" and "US$") and have been rounded to the nearest hundred thousand. Quipt will host its Earn ...

Revenue and Income - Total revenue for the three months ended June 30, 2024, was $63,967,000, an increase of 4% compared to $60,284,000 for the same period in 2023[13] - Rentals of medical equipment generated $26,739,000 in revenue, while sales of medical equipment and supplies contributed $37,228,000 for the three months ended June 30, 2024[13] - Operating income for the nine months ended June 30, 2024, was $2,953,000, compared to $2,854,000 for the same period in 2023, reflecting a slight increase[13] - Total revenue for the nine months ended June 30, 2024, was $28,642,000, up from $27,312,000 in the same period of 2023, reflecting a growth of approximately 4.8%[21] - The company reported a net cash flow provided by operating activities of $28,642,000 for the nine months ended June 30, 2024, compared to $27,312,000 for the same period in 2023, showing an increase of about 4.8%[21] Net Loss - Net loss for the three months ended June 30, 2024, was $(1,701,000), compared to a net loss of $(1,034,000) for the same period in 2023[13] - Net loss for the nine months ended June 30, 2024, was $3,653,000, compared to a net loss of $1,460,000 for the same period in 2023, indicating an increase in losses[21] - Net loss for the three months ended June 30, 2024, was $1,701,000, compared to a net loss of $1,034,000 for the same period in 2023, representing a 64.5% increase in losses[79] - The total net loss for the nine months ended June 30, 2024, was $3,653,000, compared to $1,460,000 for the same period in 2023, indicating a 150.5% increase in losses[79] Assets and Liabilities - Total current assets increased to $74,242,000 as of June 30, 2024, from $65,433,000 as of September 30, 2023, representing a growth of 13%[8] - Accounts receivable, net, rose to $31,411,000 as of June 30, 2024, compared to $25,978,000 as of September 30, 2023, marking a 21% increase[8] - Total assets amounted to $249,784,000 as of June 30, 2024, slightly up from $247,408,000 as of September 30, 2023[8] - Current liabilities increased to $66,820,000 as of June 30, 2024, from $60,574,000 as of September 30, 2023, indicating an increase of 10%[8] Expenses - The company reported a bad debt expense of $3,208,000 for the three months ended June 30, 2024, compared to $2,425,000 for the same period in 2023, reflecting a 32% increase[13] - The company reported a depreciation and amortization expense of $36,778,000 for the nine months ended June 30, 2024, compared to $28,074,000 for the same period in 2023, reflecting an increase of about 30.9%[21] - Total operating expenses for the nine months ended June 30, 2024, were $91,096,000, compared to $74,533,000 for the same period in 2023, marking an increase of 22.1%[73] Stock and Compensation - The weighted average number of common shares outstanding for the three months ended June 30, 2024, was 42,623,000, up from 40,584,000 for the same period in 2023[13] - Stock-based compensation expenses for the nine months ended June 30, 2024, was $2,154,000, down from $3,911,000 for the same period in 2023, a decrease of approximately 44.8%[21] - Total stock-based compensation for key management personnel for the nine months ended June 30, 2024, was $663,000, down from $1,669,000 in the same period in 2023[82] Financing and Debt - The company incurred $2,370,000 in financing costs related to the senior credit facility, which will be amortized over the life of the facility[49] - The total principal of the senior credit facility as of June 30, 2024, was $66,651,000, slightly up from $66,350,000 as of September 30, 2023[41] - Interest expense on the facility for the nine months ended June 30, 2024, was $3,997,000, an increase from $3,000,000 for the same period in 2023, representing a 33% rise[48] Inventory and Equipment - Inventory as of June 30, 2024, totaled $22,601,000, an increase from $18,414,000 as of September 30, 2023, representing a growth of approximately 22.4%[31] - The carrying value of equipment pledged as security against loans was approximately $13,400,000 as of June 30, 2024, compared to $8,700,000 as of September 30, 2023[53] - Equipment loans ending balance as of June 30, 2024, is $13,304,000, an increase from $5,707,000 at the beginning of the period[54] Legal and Regulatory - The company has received a civil investigative demand from the DOJ regarding potential false claims related to CPAP equipment[71] Shareholder Actions - The company has initiated a normal course issuer bid allowing for the purchase of up to 3,626,845 common shares, with a maximum expenditure of $5,000,000[60]

Quipt Home Medical Corp. (QIPT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 14, 2024, might help the stock move higher if these key numbers are b ...

CINCINNATI, July 31, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal third quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Thursday, August 15, 2024, at 10:00 a.m. (ET). The c ...

Our core strength is our incredible team, which consists of over 1,200 individuals. With the ongoing dedication to patient care and scale, weÂ're achieving, we are poised to capitalize on the expanding need for respiratory care delivered in the home setting. This need for respiratory care is driven by an aging population, significant COPD target patient group of over 16 million Americans and a significantly underpenetrated sleep apnea market with OSA impacting 80 million adults across the United States. Cas ...

• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue Revenue for Q2 2024 was $64.0 million compared to $58.1 million for Q2 2023, representing a 10% increase. Organic growth contributed approximately $3.3 million, or 6% on an annual basis. The Company absorbed a revenue impact in the quarter resulting from expiration of the Medicare 75/25 blended rate as of January 1, 2024. The Medicare 75/25 blended rate had been providing rate relief in certain geographies. Additionally, in certain regions, the Compa ...